Daily Archives: March 7, 2021
RCT: Primary tumor resection plus chemotherapy vs. chemotherapy alone for colorectal cancer patients with asymptomatic, synchronous unresectable metastases
7 Mar, 2021 | 19:23h | UTCOriginal study: No Survival Benefit to Primary Resection Before Chemo in Metastatic Colorectal Cancer – Medscape / Reuters
Primary tumor resection followed by chemotherapy in patients with metastatic colorectal cancer doesn't improve survival over chemotherapy alone https://t.co/iOYqjaABzi @JCOG_official #crcsm #JCO pic.twitter.com/RCj2OHEehH
— Journal of Clinical Oncology (@JCO_ASCO) March 5, 2021
Cardiovascular disease risk in immune-mediated inflammatory diseases: recommendations for clinical practice
7 Mar, 2021 | 19:20h | UTC
Systematic review: Big data analytics in healthcare
7 Mar, 2021 | 19:24h | UTCBig data analytics in healthcare: a systematic literature review – Enterprise Information Systems
Systematic review: High‐flow nasal cannula for respiratory support in adult intensive care patients
7 Mar, 2021 | 19:31h | UTCHigh‐flow nasal cannula for respiratory support in adult intensive care patients – Cochrane Library
Summary: High-flow nasal cannulae for breathing support in adult intensive care patients – Cochrane Library
RCT: Half-dose vs. full-dose Edoxaban in 14,014 patients with Atrial Fibrillation
7 Mar, 2021 | 19:13h | UTCCommentary: Lower Dose of Edoxaban Supported in ENGAGE-AF-TIMI 48 Analysis – TCTMD
Guidance: Perplexing Presentations (PP)/Fabricated or Induced Illness (FII) in Children
7 Mar, 2021 | 19:29h | UTCCommentary: Fabricated or induced illness in children highlighted in new guidance – University College London
RECOVERY trial: Colchicine arm stopped for lack of efficacy in patients hospitalized with COVID-19
7 Mar, 2021 | 20:16h | UTCCommentary: Cochicine does not improve mortality in COVID19 – St Emlyn’s
Commentary on Twitter
RECOVERY trial update:
Colchicine arm stopped for lack of efficacy in patients hospitalised with COVID-19.https://t.co/hcn9PytegJ pic.twitter.com/q09eddYXYL
— Martin Landray (@MartinLandray) March 5, 2021
RCT: Azithromycin provides no benefit for community treatment of patients with suspected COVID-19
7 Mar, 2021 | 20:15h | UTC
Commentary on Twitter
The PRINCIPLE trial publishes its first peer reviewed paper, showing results from the study of azithromycin as a treatment for Covid-19 in the community. @TheLancet #UrgentCovidResearch #PRINCIPLETrial
👉https://t.co/qKRI5PVpQk pic.twitter.com/BVQztDSvSC— OxPrimaryCareSci (@OxPrimaryCare) March 5, 2021
WHO: The effects of virus variants on COVID-19 vaccines
7 Mar, 2021 | 20:09h | UTCThe effects of virus variants on COVID-19 vaccines – World Health Organization
Mask mandates and restaurant restrictions tied to fewer Covid-19 illnesses and deaths, CDC study says
7 Mar, 2021 | 20:07h | UTC
Commentary on Twitter
A new @CDCMMWR finds that state-issued mask requirements are associated with the slowing of #COVID19 cases and deaths. Wearing a well-fitting mask consistently and correctly is one of the best ways we can protect ourselves and each other. Learn more: https://t.co/8YtmIMPMY0. pic.twitter.com/BLb56SGb2g
— CDC (@CDCgov) March 5, 2021
[Preprint] Genomics and epidemiology of a novel SARS-CoV-2 lineage P.1 – “P.1 may be 1.4–2.2 times more transmissible and 25-61% more likely to evade protective immunity elicited by previous infection with non-P.1 lineages”
7 Mar, 2021 | 20:05h | UTCGenomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil – medRxiv
Commentary: Brazil variant can reinfect virus survivors; COVID-19 vaccine antibodies pass into breast milk – Reuters
[Preprint] SARS-CoV-2 P.1 variant shows resistance to antibody neutralization
7 Mar, 2021 | 19:53h | UTCIncreased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization – bioRxiv
Commentary: Brazilian SARS-CoV-2 P.1 variant shows resistance to antibody neutralization – News Medical
[Medicine based on data leaks…] Oxford study indicates AstraZeneca vaccine is effective against SARS-CoV-2 Lineage P.1
7 Mar, 2021 | 19:48h | UTC
Commentary on Twitter
https://twitter.com/hildabast/status/1368010132781600773
[Preprint] Preliminary study shows Sinovac vaccine may not trigger sufficient antibody response to SARS-CoV-2 Lineage P.1
7 Mar, 2021 | 19:49h | UTCCommentary: Sinovac vaccine may not trigger sufficient antibody response to Brazil variant: study – Reuters
Commentary on Twitter
1) In a preprint (to the Lancet), the new Brazilian #SARSCoV2 variant P.1. was found to reduce the neutralizing ability of post-COVID-19 antibodies by about 6-fold, compared with the B lineage.https://t.co/obYmktWFXr pic.twitter.com/3IPiUjHB3l
— Jonathan Cedernaes (@JCedernaes) March 2, 2021
Diagnosis of non-consensus transient ischemic attacks with focal, negative, and non-progressive symptoms: population-based validation by investigation and prognosis
7 Mar, 2021 | 19:32h | UTC
Commentary on Twitter
Some patients present with symptoms that are considered not definitive for TIA (isolated dysarthria, vertigo, etc). Are these patients at risk for later stroke? Fascinating results in @TheLancet from the Oxford Vascular Study@ESOstroke @WorldStrokeOrg https://t.co/l0tJXseE3Y
— Seemant Chaturvedi (@ChaturvediNeuro) March 5, 2021
[Preprint] Increased risk of hospitalization associated with infection with SARS-CoV-2 Lineage B.1.1.7 in Denmark
7 Mar, 2021 | 19:46h | UTC
Commentary on Twitter (thread – click for more)
📍~64% MORE SEVERE—The already more contagious #B117 variant from 🇬🇧 is now found to increase risk of #COVID19 hospitalization by 64% versus other strains, says Denmark’s 🇩🇰 CDC. Denmark sequences every cases—their data is the best, & now most worrisome.🧵 https://t.co/F6w2JYEUnM pic.twitter.com/mngJoTBZtl
— Eric Feigl-Ding (@DrEricDing) March 4, 2021
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
7 Mar, 2021 | 19:43h | UTC
Commentary on Twitter (thread – click for more)
Very good and important new data on the UK variant and vaccine response
"B.1.1.7 is not a neutralization escape variant of concern for COVID-19 vaccines"
"B.1.1.7 is unlikely to increase the risk of SARS-CoV-2 re-infection"https://t.co/DWzwBUDwY3 @cellhostmicrobe pic.twitter.com/iQv7mL9MHq— Eric Topol (@EricTopol) March 4, 2021
New WHO/IAEA publication provides guidance on radiotherapy equipment to fight cancer
7 Mar, 2021 | 19:28h | UTCNews Release: New WHO/IAEA publication provides guidance on radiotherapy equipment to fight cancer – World Health Organization
Technical Document: Technical specifications of radiotherapy equipment for cancer treatment
🆕 guidance on the procurement of radiotherapy equipment released today in collaboration with @iaeaorg, aims to improve access to this life-saving #cancer treatment option that is still lacking in many parts of the world 🌎🌍🌏
👉 https://t.co/fnR0q3DDMq pic.twitter.com/21SHSaQGy7
— World Health Organization (WHO) (@WHO) March 5, 2021
Study: Cancer patients benefit from using automated device to manage their symptoms
7 Mar, 2021 | 19:21h | UTCOriginal study: Phase III Randomized Controlled Trial of eRAPID: eHealth Intervention During Chemotherapy – Journal of Clinical Oncology
Treatment effects in randomized trials using routinely collected data for outcome assessment versus traditional trials: meta-research study
7 Mar, 2021 | 19:18h | UTC
WHO Guidance: Management of people affected by lymphatic filariasis
7 Mar, 2021 | 19:26h | UTC
Conversion of Propranolol to Carvedilol in patients with cirrhosis and ascites: Small randomized, open label study suggests improvement in outcomes
7 Mar, 2021 | 19:08h | UTCConversion of Propranolol to Carvedilol Improves Renal Perfusion and Outcome in Patients With Cirrhosis and Ascites – Clinical Gastroenterology (link to abstract – $ for full-text)
Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk
7 Mar, 2021 | 19:11h | UTCOutcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Commentary: Published 2-Year Partner 3 Data Shed New Light on TAVI, SAVR Choice in Low-risk Patients – TCTMD
Quantitatively evaluating the cross-sectoral and One Health impact of interventions: A scoping review and case study of antimicrobial resistance
7 Mar, 2021 | 19:10h | UTCInfographic: Economic evaluations of One-Health interventions: an antimicrobial resistance case study
Commentary on Twitter
An exciting paper by @nichola_naylor sets out a new way to quantitatively evaluate the #OneHealth impact of interventions, using #AMR as a case study.
Read the full paper ➡️ https://t.co/IPVoa0lTMh
Download our infographic ➡️ https://t.co/vjtjgwkkOX pic.twitter.com/lzAqbcWern— LSHTM AMR Centre (@LSHTM_AMR) March 1, 2021
RCT: Biologic mesh implantation is associated with serious abdominal wall complications in patients undergoing emergency abdominal surgery
7 Mar, 2021 | 19:07h | UTCBiologic mesh implantation is associated with serious abdominal wall complications in patients undergoing emergency abdominal surgery: A randomized-controlled clinical trial – Trauma & Acute Care Surgery (link to abstract – $ for full-text)